Allemannsdata Wiki
Manual search

DOMORE DIAGNOSTICS AS

Organization number 925769681 · Aksjeselskap

Programmatic access to company data (JSON)

Source: Firmafakta. Data read and page generated 2026-09-09T04:56:18Z. HTML cache: no-store (TTL 0 seconds). Default TTL for Firmafakta JSON/API responses: 60 seconds.

Facts

Source: Firmafakta, with business data from public registers.

organisasjonsnummer:
925769681
navn:
DOMORE DIAGNOSTICS AS
organisasjonsform:
kode:
AS
beskrivelse:
Aksjeselskap
naeringskode1:
kode:
62.100
beskrivelse:
Dataprogrammeringstjenester
antallAnsatte:
9
hjemmeside:
not reported by source
epostadresse:
tomas.alme@domorediagnostics.com
telefon:
not reported by source
forretningsadresse:
adresse:
Ullernchausséen 64
poststed:
OSLO
postnummer:
0379
kommune:
OSLO
stiftelsesdato:
2020-09-17
registreringsdatoenhetsregisteret:
2020-10-23
aktivitet:
Utvikling og salg av systemer for dataanalyse av medisinske bilder.
vedtektsfestetFormaal:
Utvikling og salg av systemer for dataanalyse av medisinske bilder.

View the address in Geonorge

Board and other roles

Source: Firmafakta. Also see the separate Brønnøysund lookup under related lookups.

Daglig leder

Regnskapsfører

Revisor

Styre

Owners

Source: Firmafakta shareholder dataset.

  1. NORSELAB F I DOM AS – 25.3 % (11366000 shares, share class: Ordinære aksjer)
  2. GROTMOL SOLUTIONS AS – 10.91 % (4902000 shares, share class: Ordinære aksjer)
  3. EMIL ANDRE MOI DANIELSEN – 6.54 % (2936308 shares, share class: Ordinære aksjer)
  4. STIAN VIKJORD DANIELSEN – 6.54 % (2936308 shares, share class: Ordinære aksjer)
  5. TARJEI SVEINSGJERD HVEEM – 5.43 % (2442000 shares, share class: Ordinære aksjer)
  6. KNUT LIESTØL – 5.07 % (2279000 shares, share class: Ordinære aksjer)
  7. OLE-JOHAN SKREDE – 3.99 % (1791000 shares, share class: Ordinære aksjer)
  8. ANDREAS KLEPPE – 3.62 % (1628000 shares, share class: Ordinære aksjer)
  9. MANOHAR PRADHAN – 3.62 % (1628000 shares, share class: Ordinære aksjer)
  10. SEPP DE RAEDT – 3.26 % (1465000 shares, share class: Ordinære aksjer)
  11. DAVID JAMES KERR – 2.9 % (1302000 shares, share class: Ordinære aksjer)
  12. HANNE ARENBERG ASKAUTRUD – 2.54 % (1140000 shares, share class: Ordinære aksjer)
  13. MARCO NOVELLI – 2.54 % (1140000 shares, share class: Ordinære aksjer)
  14. JOHN ROBERT MADDISON – 1.81 % (814000 shares, share class: Ordinære aksjer)
  15. JØRN EVERT HØYEN JACOBSEN – 1.81 % (814000 shares, share class: Ordinære aksjer)
  16. TEKST HOLDING AS – 1.81 % (814000 shares, share class: Ordinære aksjer)
  17. WIDERBERG HOLDING AS – 1.81 % (814000 shares, share class: Ordinære aksjer)
  18. HANS MARTIN STRØM MOHN – 1.45 % (651000 shares, share class: Ordinære aksjer)
  19. MERETHE GREGER DANIELSEN – 1.09 % (489384 shares, share class: Ordinære aksjer)
  20. ANNA RUTH KENSETH – 1.09 % (488000 shares, share class: Ordinære aksjer)
  21. ERIKA KRISTINA LINDSTRØM – 1.09 % (488000 shares, share class: Ordinære aksjer)
  22. FRITZ ALBREGTSEN – 1.09 % (488000 shares, share class: Ordinære aksjer)
  23. JOHN ARNE NESHEIM – 1.09 % (488000 shares, share class: Ordinære aksjer)
  24. MARIA XEPAPADAKIS ISAKSEN – 1.09 % (488000 shares, share class: Ordinære aksjer)
  25. TURID KATRINE GJERSTAD TORHEIM – 1.09 % (488000 shares, share class: Ordinære aksjer)
  26. DAHMANE OUKRIF – 0.73 % (326000 shares, share class: Ordinære aksjer)
  27. BIRGITTE NIELSEN – 0.36 % (163000 shares, share class: Ordinære aksjer)
  28. WANJA KILDAL – 0.36 % (163000 shares, share class: Ordinære aksjer)

Fetch a longer owner list

Company holdings

No holdings found.

Grants and support

Sources provided through Firmafakta: Innovation Norway, the EU, the Research Council of Norway and SkatteFUNN.

Innovasjon Norge (0)

No registered grants.

EU-tildelinger (0)

No registered grants.

Forskningsrådet (2)

2 results

  1. id:
    77170
    prosjektnummer:
    346637
    prosjekttittel:
    ValidAI Clinical VALIDation and implementation of the AI-based digital biomarker Histotype Px to personalize treatment in colorectal cancer
    prosjektstart:
    2024
    prosjektslutt:
    2027
    prosjektansvarlig_navn:
    DOMORE DIAGNOSTICS AS
    organisasjonsnummer:
    925769681
    sokt_belop:
    Onkologi
    tildelt_belop:
    0.0
    virkemiddel:
    Programmer
    aktivitet:
    Brukerstyrte innovasjonsprogrammer
  2. id:
    76836
    prosjektnummer:
    345883
    prosjekttittel:
    Precision biomarker based on digital pathology and AI to guide personalized treatment decision support for colorectal cancer (CRC) patients
    prosjektstart:
    2023
    prosjektslutt:
    2023
    prosjektansvarlig_navn:
    DOMORE DIAGNOSTICS AS
    organisasjonsnummer:
    925769681
    sokt_belop:
    Algoritmer og beregnbarhetsteori
    tildelt_belop:
    0.0
    virkemiddel:
    Nettverkstiltak
    aktivitet:
    Internasjonale nettverkstiltak

SkatteFUNN (3)

3 results

  1. id:
    64982
    innsendt_dato:
    2022-07-01
    prosjektnummer:
    338638
    bedriftsnavn:
    DOMORE DIAGNOSTICS AS
    prosjekttittel:
    Development of AI algorithm for advanced histopathology image analysis to predict cancer outcomes
    organisasjonsnummer:
    925769681
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2022-11-08
    prosjekt_fra_ar:
    2022
    prosjekt_til_ar:
    2023
    sammendrag:
    DoMore Diagnostics is a pioneer in utilising artificial intelligence to increase the prognostic and predictive value of cancer tissue samples. The company is based on extensive research at top universities with deep learning to develop new diagnostic methods. The company is a spin-out from Oslo University Hospital to further develop and commercialize the algorithms. This project will ensure development of a commercially viable product that can be used to improve patient care for colorectal patients worldwide and make drug development more effective.
  2. id:
    67800
    innsendt_dato:
    2023-06-28
    prosjektnummer:
    347317
    bedriftsnavn:
    DOMORE DIAGNOSTICS AS
    prosjekttittel:
    Clinical validation of Histotype Px as a prognostic and predictive biomarker in colorectal cancer
    organisasjonsnummer:
    925769681
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2023-10-05
    prosjekt_fra_ar:
    2023
    prosjekt_til_ar:
    2025
    sammendrag:
    There is a large need and potential for better and more cost-effective care for cancer patients by personalized treatment decisions. In colcorectal cancer (CRC), surgical resection is the standard-of-care (SoC) for patients with stage II or III CRC, and for most patients surgery surgery is followed by adjuvant chemotherapy (ACT) to reduce the risk of recurrence. ACT is currently prescribed based on clinicopathologic factors, which unfortunately offers an inaccurate risk stratification. In stage II CRC, ACT prescription is controversial and often seen as an “overtreatment” as only 3,6% benefit from it. In stage III, only 20% of patients benefit from ACT, exposing 80% of patients to unnecessary toxicity. Thus, the main problem with the current SoC is the inability to accurately identify which patients will and will not benefit from chemotherapy. Recent breakthroughs in digital pathology and AI opens new opportunities to develop digital biomarkers to extract and utilize information from tumour tissue not visible to the human eye. Histotype Px, DoMore Diagnostics’ AI-driven digital pathology technology platform has the potential to provide clinicians with rapid, cost-effective and highly accurate prognostic and predictive biomarkers to guide personalized treatment decisions. The biomarker was developed on 90 million image tiles from 2500 patients with known survival outcome data, validated in a cohort of >1000 patients, and it was shown to be able to predict the risk of cancer specific death and recurrence. However, as this is a major clinical decision for each patient, additional validation studies may be required before the biomarker can be included in clinical guidelines. The proposed project consists of a series of validation studies across a range of populations to generate the evidence necessary for wide adoption of Histotype Px, to the benefit of cancer patients and their families, the broader oncology and medical community, and society as a whole.
  3. id:
    70888
    innsendt_dato:
    2024-08-23
    prosjektnummer:
    354908
    bedriftsnavn:
    DOMORE DIAGNOSTICS AS
    prosjekttittel:
    DoMore Platform
    organisasjonsnummer:
    925769681
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    not reported by source
    soknad_avslatt:
    not reported by source
    vedtaksdato:
    not reported by source
    prosjekt_fra_ar:
    2024
    prosjekt_til_ar:
    2026
    sammendrag:
    DoMore Diagnostics is a pioneer in utilising artificial intelligence to increase the prognostic and predictive value of cancer tissue samples to guide clinical decision making and personalize cancer treatment. The company is based on extensive research at top universities with deep learning to develop new diagnostic methods, and is a spin-out from Oslo University Hospital to further develop and bring its digital biomarkers into clinical practice on a global scale. This project will further improve existing products and develop a unified platform for the deployment and use of our existing and future products.

Subunits

Open positions

count:
0
stillinger:

No results.

Related lookups

How an AI agent should use this page

Ground rule: Navigate with HTML GET links to keep explanations and relationships. Use the page's JSON alternative only when concrete values must be extracted, compared or computed.

How to use the company page

  1. Use the organization number as the stable key.
  2. Distinguish between the company's own facts, roles, owners, holdings and grants.
  3. Follow person and company links to explore the graph; do not assume relations that are not explicitly registered.

Related services

Time: Ownership, roles and status can change. State the source and retrieval time with factual claims.

AI agent? Read the complete navigation and programming guide.